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principal components analysis and descending hierarchical classification. Results: 
Steps 1–3: Development and adaptation of a self-reported 44-item questionnaire on 
a 0–10 scale of fears and beliefs. 5 domains established a priori: origin of the disease, 
flares, treatments, disease progression and consequences of disease. Step 4: In the 
study of 226 patients (161 RA, 65 axSpA), all dimensions were ≥ 0.79 and ≤ 0.93, apart 
from the domain “origin of the disease” (0.67). Principal component analysis identi-
fied 6 axes (63.7% of variance explained) and the descending hierarchical analysis 
identified 9 clusters (63.7% of variance). 2 clusters were highly correlated (r2= 0.80) 
and combined into a single cluster. Based on the psychometric validation, the fol-
lowing domains were identified: fears of the disease progression/consequences (18 
items) and fears about treatment (5); beliefs related to: psychological influence (2), 
genetic influence (2), physical influence (4), diet influence (4), lifestyle (3) and diverse 
opinions (4). ConClusions: This analysis confirms the internal consistency of the 
questionnaire developed. The scoring results should help physicians to understand 
their patients’ perceptions of their disease better and eventually lead to improved 
adherence to treatment.
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objeCtives: Measuring poverty in health care settings may contribute to identifying 
patients in poverty and subsequently getting appropriate management. Although 
many scales are available to measure poverty in health, less attention has been paid 
to the poverty related quality of life. The purpose of this methodological study was to 
adapt the Poverty Related Quality of Life Questionnaire developed by Boyer and others 
(2014) into Turkish and to evaluate its psychometric properties for a Turkish patient 
population. Methods: The scale was adapted into Turkish through a translation and 
back-translation process. The content validity of the scale was assessed using expert 
approval. The psychometric properties of the scale were investigated by collecting 
data from 300 patients in 3 emergency departments from random selected hospitals 
in Ankara during the period of 1 April–30 May 2015. Results: An exploratory factor 
analysis identified that the seven-factor structure accounted for 80.1% of the total 
variance. A confirmatory factor analysis indicated a sufficient model fit for the con-
struct validity of the scale: root mean square error of approximation, 0.041; compara-
tive fit index, 0.93; general fit index, 0.97; standardized root mean square residual, 
0.050. Cronbach’s alpha for the total scale was 0.83 and each item achieved the 0.40 
standard for item internal consistency. Significant associations with socioeconomic 
and clinical indicators showed good discriminant validity. ConClusions: This study 
supports the validity and reliability of the Turkish version of Poverty Related Quality 
of Life Questionnaire. This instrument can be used to measure multiple aspects of 
poverty in the health care settings; however, as poverty and quality of life are con-
textual facts, further work is needed to test the psychometric properties of this scale 
both in Turkish and different cultures.
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objeCtives: The objective of this study was to develop and validate a decision algo-
rithm that replicates expert opinion regarding the level of disease activity in patients 
with acromegaly. Methods: A panel of key experts in endocrinology and outcomes 
research provided input as to what parameters are critical to assess disease activity. 
The top five parameters where then subsequently defined at three levels of severity. 
A final set of 243 unique health states were developed. A group of 21 expert endo-
crinologists from 5 European countries and Canada was recruited to participate 
in a discrete choice experiment. Each participant was presented with 10 common 
scenarios and 42 additional scenarios selected at random and asked to indicate 
whether the hypothetical patient was stable, having mild disease activity needing 
further evaluation, or having significant disease activity requiring clinical action. 
Concordance in decisions based on the 10 common scenarios was tested using Fleiss 
Kappa and a set of linear prediction models tested to predict outcome. Results: 
The five parameters included: 1) IGF-I level (SDS score); 2) tumor status (change 
on MRI); 3) comorbidities (number and severity); 4) signs and symptoms (Patient 
Acromegaly Symptom Questionnaire score); and 5) health-related quality of life 
(scored on a disease specific measure). The Inter-rater reliability was adequate 
(Kappa = 0.52). Based on a CART analysis, the decision model of best fit was dis-
junctive with IGF-1 and Tumor status primarily predicting the health status. The 
remaining three parameters were instructive but not deterministic. ConClusions: 
Biochemical and tumor status are the primary predictors of disease activity, with 
the patient’s perceived disease state playing a secondary role. This may highlight 
the need for a more patient-centered approach to acromegaly disease manage-
ment. To enable clinical use of the model, a disease specific tool named ACRODAT 
(ACROmegaly Disease Activity Tool) is currently in further development.
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objeCtives: To assess effects of CZP+MTX vs placebo (PBO)+MTX on patient 
reported outcomes in DMARD-naïve patients with severe, active and progressive 
RA. Methods: Patients in this double-blind randomized study (NCT01519791) 
were DMARD-naïve with active RA< 1yr diagnosis at baseline (BL), fulfilling 
2010 ACR/EULAR criteria; ≥ 4 swollen and ≥ 4 tender joints; DAS28[ESR]≥ 3.2; 
CRP≥ 10mg/L and/or ESR≥ 28mm/hr, rheumatoid factor/ACPA positive. Patients 
were randomized 3:1 to CZP (400mg Wks 0,2,4 then 200mg Q2W to Wk52)+MTX 
or PBO+MTX. MTX was initiated at 10mg/wk, increased up to 25mg/wk by Wk8, 
maximum tolerated dose maintained to Wk52. HAQ-DI, PtGADA, Pain VAS, %pts 
achieving normative physical function (HAQ-DI≤ 0.5), health-related QoL (SF-36, 
EQ-5D-3L) were assessed. At Wk52 changes from baseline (CFB) were analyzed 
using ANCOVA (LOCF imputation); categorical variables were analyzed using 
logistic regression (non-responder imputation). Data are LS mean CFB (SE) unless 
otherwise specified. Results: 660 (CZP+MTX) and 219 (PBO+MTX) patients were 
randomized; 655 vs 213 in the full analysis set (patients with baseline and post-
baselineL DAS28[ESR]). Baseline characteristics were balanced between study 
arms; mean (SD) HAQ-DI= 1.6 (0.6), Pain VAS= 66.1 (22.4), PtGADA= 65.3 (22.0). 
At Wk52, greater improvements from baseline were observed with CZP+MTX 
vs PBO+MTX in HAQ-DI (-1.0 [0.0] vs -0.8 [0.0], p< 0.001; 48.1% vs 35.7% patients 
reached normative function), pain (-48.5 [1.0] vs -44.0 [1.7], p< 0.05), PtGADA (-46.7 
[1.0] vs -42.0 [12.5], p< 0.05) and health-related QoL measured by SF-36 (physical 
component summary score= 12.4 [0.4] vs 10.7 [0.6], p< 0.01; mental component 
summary score= 8.2 [0.5] vs 6.8 [0.7]). Numerically higher proportions of CZP+MTX 
patients reported no problems in domains of the EQ-5D-3L vs PBO+MTX patients, 
including mobility, self-care, usual activities, pain/discomfort and anxiety/depres-
sion. ConClusions: In DMARD-naïve patients with severe, active and progressive 
RA, CZP+MTX showed greater improvements at 1-year in physical function, pain, 
disease activity and health-related QoL compared to PBO+MTX.
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objeCtives: To carry-out the cultural adaptation into Spanish (for Spain) of the 
questionnaire “Overactive Bladder - Family Impact Measure (OAB-FIM)”. Methods: 
The adaptation included linguistic validation through forward and back transla-
tions in duplicate, reviewed by a panel experts and a debriefing with relatives of 
OAB patients, and a phase of preliminary measurement of psychometric proper-
ties in OAB patients and their relatives of habitual coexistence, of both genders, 
≥ 18 years of age, newly diagnosed and on-therapy for their symptoms of OAB. 
Conceptual and linguistic equivalences, internal consistency (α -Cronbach), con-
tent validity (the inter-rater Rovinelli-Hambleton index of item congruence) and 
construct validity were measured. Construct validity included concurrent validity 
(with scales ZARIT and OABq-SF), and validity of known groups according to the 
benefit of treatment with TBS scale. Feasibility and burden of administration were 
also measured. Results: 25 couples of patients [mean (SD): 57.2 (16.0) years, 60% 
women] and relatives [63.0 (14.3) years, 44% women] were enrolled. The OAB-FIM 
was equivalent conceptually and linguistically to the original, remaining the six 
initial domains: activities, travel, concern, irritation, sleep and sex. Missing items 
was low (2.95%). Floor and ceiling effects varied, respectively, between 20%-28%, and 
0%-16%. The average time of completion was 5.2 (2.8) minutes. 24.0% needed some 
help to complete the questionnaire. The Rovinelli-Hambleton index ranked correctly 
all items in its domain, except for the item 10 which ranked in domains irrita-
tion and concern. α -Cronbach varied between 0.948-0.839. Correlations of OAB-FIM 
with ZARIT were high-to-moderate (0.407-0.753) and moderate-to-small with the 
OABq-SF (0.004-0.423). Relatives whose patients showed treatment benefit showed 
scores lower on the scale (lowest impact). ConClusions: A Spanish version of 
the OAB-FIM conceptually and linguistically equivalent to the original has been 
obtained. The questionnaire has shown good internal consistency, content validity 
and construct validity, together with feasibility in the Spanish culture.
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objeCtives: To develop and validate a patient-reported questionnaire assessing 
the fears and beliefs of patients suffering from rheumatoid arthritis (RA) or spon-
dyloarthritis (SpA), that could improve educational programs. Methods: Step 1: 
Qualitative research (individual patient interviews: 25 RA, 25 axial SpA [axSpA]). Step 
2: All fears and beliefs appearing in more than 10% of interviews rephrased as ques-
tions by an expert group including a patient-partner. Each question scored 0–10 (10= 
higher fears/stronger beliefs). Step 3: Preliminary questionnaire tested by cognitive 
debriefing (5 RA, 5 axSpA patients), and reproducibility through a test-retest procedure 
among 28 patients (13 RA, 15 axSpA). Step 4: Psychometric validation through a cross-
sectional study of 226 patients. Internal consistency assessed by Cronbach’s alpha, 
